Clinical data
Trade names Clarinex
AHFS/ Monograph
MedlinePlus a602002
License data
  • AU: B1
  • US: C (Risk not ruled out)
Routes of
ATC code R06AX27 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability Rapidly absorbed
Protein binding 85%
Metabolism Hepatic
Biological half-life 27 hours
Excretion 40% as conjugated metabolites into urine
Similar amount into the feces
CAS Number 100643-71-8 YesY
PubChem (CID) 124087
DrugBank DB00967 YesY
ChemSpider 110575 YesY
UNII FVF865388R YesY
KEGG D03693 YesY
ChEBI CHEBI:291342 YesY
ECHA InfoCard 100.166.554
Chemical and physical data
Formula C19H19ClN2
Molar mass 310.82
3D model (Jmol) Interactive image

Desloratadine is a tricyclic H1-antihistamine that is used to treat allergies. It is an active metabolite of loratadine.


Desloratadine is used to treat allergic rhinitis and nasal congestion.[1] It is the major metabolite of loratadine and the two drugs are similar in safety and effectiveness.[1] Desloratadine is available in many dosage forms and under many trade names worldwide.[2]

An emerging indication for desloratadine is in the treatment of acne, as an inexpensive adjuvant to isotretinoin and possibly as maintenance therapy or monotherapy.[3][4]

Side effects

Most common side-effects are fatigue, dry mouth, headache, and gastrointestinal disturbances.[1]

Mechanism of action

Desloratadine is a selective H1-antihistamine which functions as an inverse agonist at the histamine H1 receptor;[5]

It is also an antagonist at all subtypes of the muscarinic acetylcholine receptors.

It exhibits only peripheral activity since it does not readily cross the blood-brain barrier; hence, it does not cause drowsiness because it does not readily enter the central nervous system.[6]

It has a long-lasting effect and is effective in moderate and low doses.

See also


  1. 1 2 3 See S (2003). "Desloratadine for allergic rhinitis". Am Fam Physician. 68 (10): 2015–6. PMID 14655812.
  2. Desloratadine entry at international Page accessed May 4, 2015
  3. Lee HE, Chang IK, Lee Y, Kim CD, Seo YJ, Lee JH, Im M (2014). "Effect of antihistamine as an adjuvant treatment of isotretinoin in acne: a randomized, controlled comparative study". J Eur Acad Dermatol Venereol. 28 (12): 1654–60. doi:10.1111/jdv.12403. PMID 25081735.
  4. Layton AM (2016). "Top Ten List of Clinical Pearls in the Treatment of Acne Vulgaris". Dermatol Clin. 34 (2): 147–57. doi:10.1016/j.det.2015.11.008. PMID 27015774.
  5. Canonica GW, Blaiss M (2011). "Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence". World Allergy Organ J. 4 (2): 47–53. doi:10.1097/WOX.0b013e3182093e19. PMC 3500039Freely accessible. PMID 23268457.
  6. Mann R, Pearce G, Dunn N, Shakir S (2000). "Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice". BMJ. 320 (7243): 1184–6. doi:10.1136/bmj.320.7243.1184. PMC 27362Freely accessible. PMID 10784544.
This article is issued from Wikipedia - version of the 8/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.